Date: 2015-10-13
Type of information: Collaboration agreement
Compound: integrated data analysis, visualisation and simulation software for drug research
Company: BioSolveIT (UK) Optibrium (Germany)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On October 13, 2015, Optibrium™, providers of software for compound optimisation, and chemoinformatics specialist BioSolveIT, announced that they will collaborate to create seamlessly integrated data analysis, visualisation and simulation software for drug research. The two companies are known for their prediction tools for selection and optimisation of potential therapeutics, where it is essential to recognise and resolve potential problems as early as possible. Computer software for ‘virtual design’ of drug candidate molecules prior to synthesis and testing is ubiquitous in medicinal chemistry and an important time-saver in research. As part of the agreement, both companies will exchange their proprietary technologies; the first phase will incorporate a suite of high-quality predictive models of absorption, distribution, metabolism and excretion (ADME) and physicochemical properties from Optibrium\'s StarDrop™ platform as an optional feature within BioSolveIT\'s SeeSAR™ package. This will be followed by the integration of SeeSAR's capabilities to work with 3D structural information into StarDrop's unique environment that guides the design of high quality compounds.
Financial terms:
Latest news:
Is general: Yes
